Recursion, a clinical-stage TechBio company leveraging AI for drug discovery, has announced that the FDA has cleared an investigational new drug (IND) application for its Phase 1/2 trial of REC-1245. This new chemical entity targets biomarker-enriched solid tumors and lymphoma by modulating RBM39, a novel regulatory protein identified by Recursion’s AI-enabled platform. REC-1245, which rapidly progressed from novel target biology to preclinical development, holds potential as a first-in-class RBM39 degrader. Preclinical data suggest that REC-1245 induces splicing defects, downregulating critical DNA Damage Response networks, offering hope for patients with limited treatment options.
Recursion, headquartered in Salt Lake City, integrates technology, biology, and chemistry through its advanced platform, Recursion OS. This platform utilizes one of the world’s largest proprietary biological and chemical datasets and advanced machine learning to decode biological relationships and expedite drug discovery. By performing millions of weekly lab experiments and employing a powerful supercomputer, Recursion advances novel therapeutics at an accelerated pace. With global offices, the company aims to address unmet medical needs through innovative treatments, including REC-1245, which will begin trials by the end of 2024.
